Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)

Inclusion Criteria

• •Diagnosis of diabetes mellitus in the study eye, with disease onset any time prior to the Screening Visit
• •Previously treated with at least 1 intravitreal anti-VEGF in the last 6 months in the study eye at least 8 weeks prior to the Screening Visit.
• •BCVA letter score of 35 letters (20/200 Snellen equivalent) to 75 letters (20/32 Snellen equivalent) in the study eye at the Screening Visit and at Baseline (Day 1).